Incyte Corporation Reports 2012 Fourth-Quarter and Full-Year Financial Results; Provides 2013 Financial Guidance; Updates Shareholders on Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reported fourth-quarter and full-year 2012 financial results, including revenue from Jakafi®(ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also provided 2013 financial guidance and updated information about key clinical programs, including key Phase III data for Jakafi that was presented at the 2012 American Society of Hematology (ASH) Annual Meeting.